Effect Of Ipab Abolition On Ip Litigation.
Effect of IPAB Abolition on IP Litigation
The IPAB (established in 2003) was a quasi-judicial body in India hearing patent, trademark, and design disputes, including oppositions, revocations, and appeals. It was abolished in April 2021 via the Tribunal Reforms Act, 2021, and its functions were transferred to High Courts.
Key Impacts:
Transfer of appeals from IPAB to High Courts increased case load and litigation costs.
Delay in decisions due to High Court procedural complexity.
Potential rise in forum shopping and inconsistent precedents.
Limited specialized expertise compared to IPAB judges, potentially affecting technical patent disputes.
Case Studies Illustrating IPAB Abolition Impact
1. Novartis AG v. Union of India (Patent Litigation)
Facts
Novartis challenged rejection of its Glivec patent.
Previously, post-IPAB abolition, appeals moved directly to the Delhi High Court instead of IPAB.
Legal Issues
Patent grant and opposition appeals now directly under High Court jurisdiction
Procedural delay due to High Court backlog
Outcome
Decision took longer than IPAB-era timelines
High Court upheld rejection, but litigation cost increased significantly
Significance
Shows that abolition of IPAB increased procedural burden for complex pharmaceutical patents
High Courts lack the technical panel system that IPAB had for pharmaceutical disputes
2. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (Compulsory Licensing / Patent Dispute)
Facts
Roche challenged a generic drug launch by Cipla under patent infringement and revocation claims.
Previously, IPAB would hear appeals from Controller General of Patents, now the High Court handles it.
Legal Issues
Handling of revocation and infringement appeals without IPAB’s technical expertise
Increased litigation timeline and cost
Outcome
High Court upheld controller’s order but noted long delays compared to IPAB-era efficiency
Significance
Highlighted need for specialized IP benches in High Courts
Companies must plan for extended litigation timelines
3. Pfizer Inc. v. Union of India (Trademark & Patent Enforcement)
Facts
Pfizer faced disputes regarding trademark oppositions and patent extensions.
Post-IPAB abolition, appeals are now in High Court rather than IPAB.
Legal Issues
Delays in interim injunctions due to High Court procedural rules
Enforcement of foreign patent rights affected by jurisdiction transfer
Outcome
Pfizer experienced slower injunctions and procedural bottlenecks
Some companies sought settlements instead of protracted litigation
Significance
Demonstrates that IPAB’s expertise expedited cross-border IP enforcement
Abolition shifted the litigation strategy toward High Court filings
4. Bayer v. Natco Pharma (Compulsory Licensing / Patent Opposition)
Facts
Natco applied for generic drug production under compulsory license
Bayer’s appeal from patent controller would have gone to IPAB earlier; now it goes to High Court
Legal Issues
Procedural delay and backlog impact on pharma patent timelines
Interim reliefs harder to secure
Outcome
High Court granted interim reliefs but noted longer timelines and higher costs
Decision on appeal took significantly longer than IPAB-era cases
Significance
Companies must anticipate delayed injunctions and appeal resolutions
Abolition may slow generic drug market entry disputes
5. Infosys Technologies v. Controller General of Patents (Software Patent / Design)
Facts
Infosys challenged rejection of a software-related patent/design
Under IPAB, appeal would have been fast-tracked; post-abolition, High Court handles it
Legal Issues
High Court may lack technical IP specialization
Software patent disputes require expertise in algorithms and tech applications
Outcome
High Court proceedings delayed due to complex technical evidence
Parties hired technical experts to assist judges, increasing litigation cost
Significance
Abolition affects speed and technical handling of IT/software patents
Encourages calls for specialized IP benches in High Courts
6. Cadila Healthcare Ltd. v. Controller General of Patents (Pharmaceuticals)
Facts
Cadila challenged patent revocation orders for a drug formulation.
Case transferred directly to High Court post-IPAB abolition.
Legal Issues
Delays in hearing and final orders
Impact on market exclusivity and launch timelines
Outcome
High Court upheld controller’s decision, but litigation duration doubled compared to IPAB
Companies increasingly prefer settlement or licensing over prolonged appeals
Significance
Shows commercial impact of IPAB abolition on pharma sector
Incentivizes alternative dispute resolution (ADR) in IP disputes
Key Observations – Impact of IPAB Abolition
| Aspect | Effect |
|---|---|
| Litigation Timeline | Increased by 1–2 years on average due to High Court procedural load |
| Technical Expertise | High Courts lack IPAB’s specialized technical panels; affects pharma/software patents |
| Cost of Litigation | Higher due to longer hearings, expert witnesses, and procedural complexity |
| Interim Relief / Injunctions | Harder to secure; delays affect commercial interests |
| Forum Shopping | Possible rise due to multiple High Court jurisdictions |
| Alternative Mechanisms | ADR, WIPO mediation, and settlements increasingly used |
Conclusion
IPAB abolition has led to longer, costlier IP litigation in India.
High Courts handle more complex technical matters, sometimes requiring expert assistance.
Strategic adjustments: Companies now focus on settlements, licensing, and arbitration.
Future trend: Calls for specialized IP benches in High Courts to replicate IPAB efficiency.
RELATED Blog
comments